Development of advanced therapies in cancer using a high loaded targeted delivery platform

Spirea正在通过应用其专有和经过验证的核心聚合物平台技术来应对下一代癌症疗法开发商面临的挑战。正在开发新类别的创新药物，以通过精确医学提高用于治疗癌症的强效药物的有效性和安全性。在这些技术中，药物是专门针对癌细胞的，而健康细胞没有受到影响。这有可能显著改善患者的护理，更重要的是，减少副作用。尽管有证据表明治疗方法有所改善，但由于技术挑战以及稳定性问题，这些产品进入市场的数量一直有限。这项创新将Spirea现有的靶向药物输送专利技术应用于这一癌症治疗的新领域。该项目的目标是通过技术评估、生成实验证据以及通过客户参与制定产品开发计划，使用我们的使能聚合物技术来生成一个强大的新治疗平台。该项目的结果将是，Spirea将建立一个为客户创造附加值的平台技术，具有真正的增长潜力。

Spirea is responding to challenges faced by the developers of next-generation cancer therapies, by applying its proprietary and proven core polymer platform technology. New classes of innovative pharmaceutical products are being developed to improve the effectiveness and safety of the potent drugs used to treat cancer, through precision medicine. In these techniques the drugs are directed specifically at cancerous cells, while leaving healthy cells untouched. This has the potential to significantly improve patient care, and crucially, reduce side effects. Despite evidence for improved treatment, the number of these products reaching the market has been limited due to technical challenges, along with stability issues. This innovation applies Spirea’s existing proprietary technology of targeted drug delivery, to this new field in cancer therapy. The objective of the project is to generate a powerful new therapy platform using our enabling polymer technology, through technical evaluation, generating experimental evidence, in parallel to product development planning through customer engagement. The results of the project will be that Spirea will establish a platform technology that will create added value for customers, with real potential for growth.